ProQR Therapeutics N.V. (PRQR): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biotech company tackles genetic disorders with cutting-edge RNA therapies? ProQR Therapeutics N.V. is pioneering a unique approach, but how exactly does it work and what's their financial standing? With €149.4 million in cash reserves as of the end of 2024 and significant partnerships, including one with Eli Lilly, ProQR is striving to transform the treatment of diseases through its Axiomer RNA editing platform, with plans to have up to four clinical data readouts throughout 2025 and 2026. Keep reading to discover the history, ownership structure, mission, and revenue model of this innovative company.

ProQR Therapeutics N.V. (PRQR) History

ProQR Therapeutics N.V. Founding Timeline

Year established

The company was established in 2012.

Original location

The company was founded in Leiden, the Netherlands.

Founding team members

The founding team included Dinko Valerio, who served as CEO.

Initial capital/funding

In 2012, the company secured a €6.5 million seed financing round led by Vesalius Biocapital.

ProQR Therapeutics N.V. Evolution Milestones

ProQR Therapeutics N.V. Transformative Moments

• Focus on RNA Therapies: A key transformative moment was the company's unwavering focus on RNA-based therapies to treat genetic diseases. This commitment shaped its research and development strategy.
• Axiomer RNA Editing Technology: The development and focus on the Axiomer RNA editing platform marked a significant shift. This technology aims to correct genetic mutations directly, potentially offering more precise and effective treatments.
• Strategic Partnerships: Collaborations with companies like Galapagos NV provided not only financial resources but also validation of ProQR's technology and approach, influencing its strategic direction.
• Pipeline Reprioritization: The decision to reprioritize its pipeline and focus on Axiomer, while discontinuing other programs, was a crucial moment that reflected a strategic adaptation to maximize the potential of its most promising technology.
• Reverse Merger with инвестиционная компания: The reverse merger with инвестиционная компания represents a transformative step, providing new capital and a renewed focus on advancing the Axiomer platform under a new company name.

ProQR Therapeutics N.V. (PRQR) Ownership Structure

Understanding a company's ownership structure is crucial for investors and stakeholders, as it provides insights into control, decision-making, and potential alignment of interests. The following sections break down the ownership of ProQR Therapeutics N.V., its current status, and key leadership figures as of April 2025.

ProQR Therapeutics N.V. Current Status

ProQR Therapeutics N.V. is no longer trading. The company was officially delisted from the stock market on November 13, 2023, after its acquisition by Eli Lilly and Company. This acquisition means that ProQR is now a private entity, fully integrated into Eli Lilly.

ProQR Therapeutics N.V. Ownership Breakdown

As ProQR Therapeutics N.V. is now a wholly-owned subsidiary of Eli Lilly and Company, the ownership structure has fundamentally changed. The previous distribution of shares among various holders is no longer applicable. As of April 2025, 100% of ProQR Therapeutics N.V. is owned by Eli Lilly and Company.

ProQR Therapeutics N.V. Leadership

Following the acquisition by Eli Lilly, the leadership structure of ProQR Therapeutics N.V. has been integrated into Eli Lilly's organizational framework. While specific roles and titles may have evolved, key personnel are now part of Eli Lilly's broader research and development teams. It is important to note that the information available prior to the acquisition may no longer be current. For insights into the company's mission and values before its acquisition, you can refer to: Mission Statement, Vision, & Core Values of ProQR Therapeutics N.V. (PRQR).

ProQR Therapeutics N.V. (PRQR) Mission and Values

The company's mission was centered on transforming the lives of patients with rare genetic eye diseases through the development of RNA therapies. Although the company no longer exists in its original form, its mission and values provide insight into its past aspirations.

Core Purpose

Official mission statement

The former mission statement of the company was: 'To transform the lives of patients with rare genetic eye diseases.' This was to be achieved by the discovery and development of RNA therapies targeted at the underlying genetic cause of these diseases.

Vision statement

While a specific vision statement may not have been explicitly declared, the vision can be inferred from their activities and goals:

• To become a leader in the development of RNA-based therapies for genetic eye diseases.
• To provide effective treatments for conditions where limited or no options were available.
• To improve the quality of life for patients and families affected by these debilitating conditions.

Company slogan/tagline

While the company may not have had a formal slogan, their focus on addressing the root genetic causes of diseases through RNA therapies effectively communicated their innovative approach. The emphasis was on pioneering new treatments and offering hope to patients with inherited retinal diseases. More information about the company and its investors can be found at: Exploring ProQR Therapeutics N.V. (PRQR) Investor Profile: Who’s Buying and Why?

ProQR Therapeutics N.V. (PRQR) How It Works

ProQR Therapeutics N.V., which focused on developing RNA therapies for genetic eye diseases, ceased operations in 2022. The company aimed to create therapies that address the underlying cause of genetic disorders by using oligonucleotides to repair or modify RNA.

ProQR Therapeutics N.V.'s Product/Service Portfolio

Historically, ProQR Therapeutics N.V. focused on developing RNA-based therapies. While the company is no longer operational, its key programs and target markets are outlined below to provide context.

ProQR Therapeutics N.V.'s Operational Framework

ProQR Therapeutics N.V. operated with a focus on:

• RNA-based Drug Development: Using antisense oligonucleotides to target specific RNA sequences, aiming to correct genetic mutations.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates. For example, Sepofarsen underwent Phase 1/2 and Phase 3 trials.
• Partnerships: Collaborating with research institutions and other companies to advance their pipeline and expand their capabilities.

ProQR Therapeutics N.V.'s Strategic Advantages

Before ceasing operations, ProQR Therapeutics N.V. had several potential strategic advantages:

• Novel Technology: Focused on pioneering RNA-based therapies for genetic eye diseases.
• Orphan Drug Designation: Targeting rare genetic disorders, which often qualify for orphan drug designation, providing regulatory and market exclusivity benefits.
• Targeted Approach: Developing therapies that address the underlying genetic cause of diseases, potentially offering more effective and durable treatments.

To gain more insights into the values that guided the company, you can explore: Mission Statement, Vision, & Core Values of ProQR Therapeutics N.V. (PRQR).

ProQR Therapeutics N.V. (PRQR) How It Makes Money

The company primarily focused on discovering and developing RNA-based therapeutics for the treatment of severe genetic diseases. Revenue generation was primarily through strategic collaborations, licensing agreements, and milestone payments related to the progress of their drug development programs. As of recent updates, the company has shifted its strategic direction.

ProQR Therapeutics N.V. Revenue Breakdown

As a company that has undergone significant restructuring and strategic shifts, precise, up-to-date revenue breakdowns are subject to change. Historically, revenue streams were heavily reliant on collaborative agreements and milestone achievements. Given the company's recent pivot, the future revenue streams may evolve considerably.

For detailed insights into the investor landscape, check out: Exploring ProQR Therapeutics N.V. (PRQR) Investor Profile: Who’s Buying and Why?

ProQR Therapeutics N.V. Business Economics

The business economics of the company were historically centered around the high-risk, high-reward model typical of biotechnology firms. Key aspects included:

• R&D Investments: Significant capital was allocated to research and development, a common trait in the biotech sector.
• Partnerships: Strategic alliances were crucial for funding and expertise.
• Intellectual Property: Patents and proprietary technologies formed a core asset.

Given the company's strategic shift, these economics are likely to evolve. The success of the company depends on the new direction and how well they can execute it.

ProQR Therapeutics N.V. Financial Performance

Evaluating the financial performance of the company requires a look at key indicators, which have likely been impacted by the strategic shift. Historically, these included:

• Cash Runway: Monitoring cash reserves was vital, especially given the high burn rate associated with R&D.
• Net Losses: The company, typical of biotech firms, often reported net losses due to heavy investment in drug development.
• Stock Performance: Stock value was sensitive to clinical trial results and partnership announcements.

Investors should closely monitor financial reports and company announcements to understand the implications of the strategic shift on the company's financial health.

ProQR Therapeutics N.V. (PRQR) Market Position & Future Outlook

As of April 2025, ProQR Therapeutics N.V. faces a dynamic landscape in the RNA therapeutics market, balancing promising advancements with inherent challenges. The company's future success hinges on its ability to navigate regulatory hurdles, secure funding for ongoing research, and demonstrate clinical efficacy in its lead programs.

Competitive Landscape

Opportunities & Challenges

Industry Position

ProQR Therapeutics N.V. occupies a niche position within the broader RNA therapeutics market, distinguished by its emphasis on addressing specific genetic mutations that cause rare diseases. This targeted approach allows for the development of personalized therapies, but also presents challenges in terms of patient population size and market access. Here are some key aspects of their industry position:

• Focus on Rare Diseases: The company's pipeline is heavily focused on rare genetic disorders, providing opportunities for orphan drug designations and accelerated regulatory pathways.
• RNA-Based Therapies: ProQR specializes in RNA-based therapeutics, including antisense oligonucleotides and RNA editing technologies, which offer the potential to correct genetic defects at the RNA level.
• Partnerships: Strategic alliances with research institutions and pharmaceutical companies are vital for advancing drug development and expanding market reach.

To gain more insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of ProQR Therapeutics N.V. (PRQR).